Clinical Trials Browser

Phase 1 × Fanconi Anemia, Complementation Group D1 × Breast × Clear all

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Ovarian Neoplasms

NCT01286987 2019-01-10

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

BreastClassical hematologyGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fanconi Anemia, Complementation Group D1, Carcinoma, Ovarian Epithelial, Breast Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Ewing, Small Cell Lung Carcinoma

Clinical Trials

REVIVAL

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors